Non-puerperal Mastitis
Conditions
Interventions
Non-puerperal Mastitis Patients:Methylprednisolone tablets, oral, the initial dose of 0.5 mg/kg/d, continuous treatment for 10 days, if the patients symptoms are relieved, that is, the redness and swe
Sponsors
The First Affiliated Hospital of Nanjing Medical University
Eligibility
Sex/Gender
Female
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1) Non-lactating women aged 18-70 who are willing to sign an informed consent form and are able to comply with the requirements of the protocol; 2) Patients whose clinical and pathological diagnosis were consistent with non-puerperal mastitis; 3) First onset, no previous history of antibiotics and glucocorticoid therapy; 4) Imaging examination of breast ultrasound, breast X-ray, breast magnetic resonance imaging (plain scan + enhanced) and other assessments, in addition to the target lesions, there were no other suspicious malignant (BI-RADS category 4 and above) breast tumors.
Exclusion criteria
Exclusion criteria: The study was excluded if any of the following conditions were met: 1) When the patient is first diagnosed, the local skin of the breast has obvious redness and swelling, local abscess has been formed or has been in the refractory stage, that is, the local ulceration, fistula or sinus has been formed in the breast; 2) Pathological diagnosis of inflammatory breast cancer, breast tuberculosis, foreign body granuloma, IgG4-related breast sclerosing inflammation and other diagnoses; 3) complicated with hyperprolactinemia; 4) Tuberculin test indicated active phase of Mycobacterium tuberculosis infection; 5) combined with other parts and organ infections; 6) fibroadenoma, cyst and breast cancer were considered clinically combined with breast ultrasound, mammography or breast magnetic resonance imaging; 7) Patients could not complete the questionnaire due to mental illness, educational level or other reasons; 8) any instability or conditions that may jeopardize the patient's safety and compliance in this study; 9) patients participating in other clinical trials; 10) Other diseases or symptoms that the investigator deemed unsuitable for participation in the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Cure rate;Remission rate;Recurrence rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| Incidence of adverse events; | — |
Countries
China
Contacts
Public Contactshui wang
Breast Disease Center, the First Affiliated Hospital of Nanjing Medical University
Outcome results
None listed